|
"Pharmaceutical industry is a tough industry, where there is no chance speculation. Even if it did it was a drama in the clown, the concern may be temporary, but can not control the final voice." Wang Haibo and Fudan Zhangjiang in the body, we can also see the difficulties the Chinese engaged in drug R & D index and hopes index. 1996, at the Fudan University campus, an office, was still teaching in Fudan University and Fudan University are producing Wang Haibo, director Jiang Guoxing do teachers negotiate. To discuss the theme of the development of Shanghai Pudong New Area biomedical throw the olive branch, but the result took the conversation Wang Haibo started another round of life. Subsequently, he accepted the invitation of the Pudong New Area, Pudong New Area government investment in the 3 million yuan and 500,000 yuan investment in the Zhangjiang Hi-Tech Park was established on the basis of the "Fudan Zhangjiang." At the sight of Chinese pharmaceutical industry, in fact, mainly fine chemical industry, in addition to almost no Chinese had invented something. At that time the legal environment for patent protection in China is still very immature, a general lack of power business innovation. In this environment, Wang Haibo has been such a concept: the 1.3 billion people, China to nurture an ability to truly make the medicine makers, the scientific theory into drugs. Now, new drugs on the life experiences in the past 10 years, Fudan Zhangjiang, even already have 4 ~ 5 larger drug system, Wang Haibo still emphasize doing drugs must have the patience of a long-term , there must be a little humane care, in the process can not tolerate any speculation. Glad he is in Shanghai Zhangjiang, many drug development companies and he has the same idea. "Sell first child" 1996, the Fudan University took over development of the Pudong New Area, the feasibility of biomedical research, Wang Haibo, who is in charge of the subject. Recall the years of hardship, he admitted that was no thought of doing a new drug would take so long, so hard. New drug development is a high input, high risk, long-cycle industries. In general, the drug development cycle at least 10 years, require huge R & D expenditures, success rate is only 1 / 5000. In this process, there is more to pave the way type of drug development companies, they may be anything from setting up to the bankruptcy did not succeed. In China, almost all of the new drug development companies are hard to get rid of "sell first child," the common experience. Present, the first tier of domestic innovation and drug companies are generally the beginning of the project is to build the basic system, to survive until after the development of this system as their platform. Fudan Zhangjiang is also true. Structures with limited resources can make the outcome of primary research and development system for large pharmaceutical companies to do R & D foundry, to do technology exports, this process about 2 years in Zhangjiang. Wang Haibo told reporters, "to sell their first child," a possible technical capacity of the enterprise itself can not support the walk down, for instance, found a compound, but the process can not be achieved towards medicine; another possible is difficult to meet their financial ability to drug development needs. Fudan Zhangjiang Zi Corporation CCR5 drug and drug company bought the Australian final is a pharmaceutical company. The drug as a fourth-generation AIDS drugs, the price will be very expensive, if the market recovered from its future research and development costs, must be global operations. The new drug approval mechanism at home and abroad has tremendous difference case, every step of the in-depth research and development and certification will require substantial financial support. Wang Haibo applications for the pharmaceutical patents in 12 countries. However, after the patent application to the necessary implementation, not the implementation, this patent protection, there is no meaning. But he did not so much capital to support further R & D and market development. Money will not do if , Of course, "selling a child" is to the future that he can "raise children", with the gradual adjustment of domestic drug policy in place, suitable drugs are beginning to build. Wang Haibo that from the situation in recent years, China's drug innovation is still a difficult process. Make a new drug takes 10 years, and now the decision-making influence is the next 10 years, and if from the next 10 years, China's new drug on the pharmaceutical industry's contribution to value will be gradually increased to reach 50% believe that the contribution rate . Currently, new drugs in China is not a luxury to do things, our intellectuals, both from a technical or medical profession in understanding has gradually grown and matured, and new drug development goals, the key to the capital will be crucial. In the United States, NIHR (National Disability Institute) to provide financial support to SMEs to do a lot of new drug development, domestic enterprises are basically self-financing in doing so, almost all domestic innovative drugs companies are facing financial difficulties. We are high quality suppliers, our products such as usb wifi antenna adapter , wireless 150mbps adapter Manufacturer for oversee buyer. To know more, please visits wireless 54mbps adapter.
Related Articles -
usb wifi antenna adapter, wireless 150mbps adapter Manufacturer,
|
